Stem Cell Clinic

Stem Cell Therapy Market expected to reach USD 16.51 Billion by 2025 KSU | The Sentinel Newspaper – KSU | The Sentinel Newspaper

By adminMarch 8, 2021Stem Cell Medicine

Stem Cell Therapy Market is valued at USD 9.32 Billion in 2018 and expected to reach USD 16.51 Billion by 2025 with the CAGR of 8.5% over the forecast period.

In its latest report on Stem Cell Therapy Market provides a concise analysis of the recent market trends. The report further includes statistics, market forecasts and revenue estimations, which in addition highlights its status in the competitive domain as well as expansion trends adopted by major industry players.

Rising prevalence of chronic diseases, increasing spend on research & development and increasing collaboration between industry and academia driving the growth of stem cell therapy market.

Get Sample of This [emailprotected] https://brandessenceresearch.com/requestSample/PostId/1246

*The sample pages of this report is immediately accessible on-demand.**

Scope of Stem Cell TherapyMarket-

Stem cells therapy also known as regenerative medicine therapy, stem-cell therapy is the use of stem cells to prevent or treat the condition or disease. Stem cell are the special type of cells those differentiated from other type of cell into two defining characteristics including the ability to differentiate into a specialized adult cell type and perpetual self-renewal. Under the appropriate conditions in the body or a laboratory stem cells are capable to build every tissue called daughter cells in the human body; hence these cells have great potential for future therapeutic uses in tissue regeneration and repair. Among stem cell pluripotent are the type of cell that can become any cell in the adult body, and multipotent type of cell are restricted to becoming a more limited population of cells.

The stem cell therapy has been used to treat people with conditions including leukemia and lymphoma, however this is the only form of stem-cell therapy which is widely practiced. Prochymal are another stem-cell therapy was conditionally approved in Canada in 2012 for the treatment of acute graft-vs-host disease in children those are not responding to steroids. Nevertheless, hematopoietic stem cell transplantation is the only established therapy using stem cells. This therapy involves the bone marrow transplantation.

Stem cell therapy market report is segmented based on type, therapeutic application, cell source and by regional & country level. Based upon type, stem cell therapy market is classified into allogeneic stem cell therapy market and autologous market.

Based upon therapeutic application, stem cell therapy market is classified into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases and other applications. Based upon cell source, stem cell therapy market is classified into adipose tissue-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, cord blood/embryonic stem cells and other cell sources

The regions covered in this stem cell therapy market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of stem cell therapy is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Stem Cell TherapyCompanies:

Stem cell therapy market report covers prominent players like,

Osiris Therapeutics, Inc

MEDIPOST

Anterogen, Ltd.

Cynata

Pharmicell

Cytori Therapeutics

Holostem Terapie Avanzate S.r.l.

JCR Pharmaceuticals

NuVasive

RTI Surgical

STEMCELL Technologies

BIOTIME

Osiris Therapeutics

Human Longevity

Advanced Cell Technology

Promethera Biosciences

Mesoblast and AlloSource

others

Stem Cell TherapyMarket Dynamics

Rising spend on research and development activities in the research institutes and biotech industries driving the growth of the stem cell therapy market during the forecast period. For instance, in January 2010, U. S. based Augusta University initiated Phase I clinical trial to evaluate the safety and effectiveness of a single, autologous cord blood stem infusion for treatment of cerebral palsyin children. The study is estimated to complete in July 2020. Additionally, increasing prevalence of chronic diseases creating the demand of stem cell therapy. For instance, as per the international diabetes federation, in2019, around 463 million population across the world were living withdiabetes; by 2045 it is expected to rise around 700 million. Among all 79% of population withdiabeteswere living in low- and middle-income countries. These all factors are fuelling the growth of market over the forecast period. On the other flip, probabilities of getting success is less in the therapeutics by stem cell may restrain the growth of market. Nevertheless, Advancement of technologies and government initiative to encourage research in stem cell therapy expected to create lucrative opportunity in stem cell therapy market over the forecast period.

Stem Cell TherapyMarketRegional Analysis

North America is dominating the stem cell therapy market due increasing adoption rate of novel stem cell therapies fueling the growth of market in the region. Additionally, favorable government initiatives have encouraging the regional market growth. For instance, government of Canada has initiated Strategic Innovation Fund Program, in which gov will invests in research activities carried out for stem cell therapies. In addition, good reimbursing scheme in the region helping patient to spend more on health. Above mentioned factors are expected to drive the North America over the forecast period.

Asia Pacific is anticipated to grow at a highest CAGR over forecast period due to rising awareness of benefits of stem cell therapies among the population. In addition, increasing collaboration between industry-academia to initiate research and development in the stem cell therapy expected to create the huge growth over the forecast period. For instance, as per the report of Pharma Focus Asia, members of Asia-Pacific Economic Cooperation collaborated with Life Sciences Innovation Forum to involve professionals having expertise in stem cell therapies from academia and research centers to promote developments in stem cell research which will foster regional market growth.

Key Benefits for Stem Cell TherapyMarketReports

Global Market report covers in depth historical and forecast analysis.

Global Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.

Global Market report helps to identify opportunities in market place.

Global Market report covers extensive analysis of emerging trends and competitive landscape.

Stem Cell TherapyMarketSegmentation

By Type

By Therapeutic Application

By Cell Source

Regional & Country Analysis North America, U.S., Mexico, Canada , Europe, UK, France, Germany, Italy , Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa

Table of Content

1.1. Research Process

1.2. Primary Research

1.3. Secondary Research

1.4. Market Size Estimates

1.5. Data Triangulation

1.6. Forecast Model

1.7. USPs of Report

1.8. Report Description

2.1. Market Introduction

2.2. Executive Summary

2.3. Global Stem Cell Therapy Market Classification

2.4. Market Drivers

2.5. Market Restraints

2.6. Market Opportunity

2.7. Stem Cell Therapy Market: Trends

2.8. Porters Five Forces Analysis

2.9. Market Attractiveness Analysis

Continued

Full Research Report @ https://brandessenceresearch.com/healthcare/stem-cell-therapy-market-size

About Us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Article: https://businessstatsnews.com

Blog: http://www.dailyindustrywatch.com

Read the original:
Stem Cell Therapy Market expected to reach USD 16.51 Billion by 2025 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper

New Controversy for Stem Cell Therapy That Repairs Spinal Cords – The Great Courses Daily News

By adminMarch 8, 2021Stem Cell Medicine

By Jonny Lupsha, Current Events Writer An alternative to using human embryonic stem cells is to use pluripotent stem cells, which refers to the ability of a stem cell, such as skin cells from an adult, to give rise to other differentiated cell types. Photo By Yurchanka Siarhei / Shutterstock

Patients who have received treatment from their own stem cells to repair their spinal cords are at the center of controversy after the stem cell therapy was fast-tracked in Japan in 2018. Despite 13 patients showing considerable recovery in response to the treatment, the means to this end have suggested improper shortcuts taken in the last several years.

It isnt the first time that stem cell research has been in the spotlight for ethical reasons. One controversial method of obtaining stem cells is to take them from human embryos, which has been argued about for decades. However, alternatives to embryo use are coming to pass.

In his video series Biochemistry and Molecular Biology: How Life Works, Dr. Kevin Ahern, Professor of Biochemistry and Biophysics at Oregon State University, said much about stem cells and the science that surrounds them.

There are two things that are special about stem cells, Dr. Ahern said. One is that they are capable of dividing indefinitelythat is, as long as the organism is alive. The other is that they are undifferentiatedtheyre like a child who hasnt yet chosen whether to be an astronaut, ballerina, surgeon, or an artist.

Dr. Ahern said that when stem cells divide, they can either differentiate and become a specialized cell or they can go back into the stock of stem cells. In an embryo, at the earliest stages of development, the fertilized egg divides to produce a certain number of unspecialized cells called embryonic stem cells. They become specialized by receiving certain signals, so scientists can learn what these signals are and send them to unspecialized cells to make them develop as they wish. This could mean making them become cells to repair nerve damage, heart muscles, and more.

However, some see this as tampering with nature and/or stealing cells from the embryo. Regardless of our opinions one way or the other, these ethical concerns have been raised, prompting scientists to find alternatives.

How else can stem cells be obtained, if not from embryos?

One solution is the production of what are called induced pluripotent stem cells, or iPS cells, Dr. Ahern said. Pluripotent refers to the ability of a stem cell to give rise to other differentiated cell types. To do this and yet avoid working with cells from a human embryo, scientists begin with differentiated somatic cells [like] cells from the skin of an adult, for example.

Once theyve isolated the differentiated somatic cells, scientists reverse engineer them into a state in which they can become any number of differentiated cells or tissues. Dr. Ahern said that iPS cells have been used to create beating heart cells, motor neurons, light-sensing photoreceptor cells, insulin-producing pancreatic cells, and more.

In 2017, Japanese researchers reported that monkeys with Parkinsons showed great improvement after treatment with dopamine-producing neurons derived from iPS cells, Dr. Ahern said. In 2018, clinical trials with humans were begun using iPS cells to treat Parkinsons, heart disease, and macular degeneration.

For now, stem cell therapy remains no stranger to controversyor results. The debate raging around them will likely continue in one way or another for some time.

Edited by Angela Shoemaker, The Great Courses Daily

The rest is here:
New Controversy for Stem Cell Therapy That Repairs Spinal Cords - The Great Courses Daily News

Cell Therapy for Cartilage Regeneration Gets a Boost With Hyaluronic Acid Enriched Chondrocytes in a 3D Tissue Engineering Platform – Business Wire

By adminMarch 8, 2021Stem Cell Medicine

TOKYO--(BUSINESS WIRE)--Regenerative therapy to treat knee joint damages gets a boost with a breakthrough technology of growing ideal type of cartilage cells including chondroprogenitors and mesenchymal stem cells enriched with hyaluronic acid (HA), reported by Dr Shojiro Katoh, President, Edogawa Hospital in The KNEE journal (https://doi.org/10.1016/j.knee.2021.02.019). Edogawa Evolutionary Laboratory of Science (EELS) researchers accomplished this feat using a 3D tissue engineering scaffold, without externally added HA or growth factors. They hope this technology will improvise the clinical outcome of Autologous Chondrocyte Implantation (ACI) and Matrix Assisted Chondrocyte Implantation (MACI) treatments.

Regenerative medicine applications for articular cartilage repair require growing chondrocytes taken from patients own joint, in the lab, followed by transplantation to the disease affected portion, enable them restore, replace, rejuvenate or regenerate the cartilage in ACI or MACI procedures, practiced by orthopedicians and arthroscopy surgeons worldwide. The lab environment makes the chondrocytes, many a time, grow as fibrocartilage, whereas, hyaline cartilage is the ideal type of tissue required, which contributes to weight bearing function of the joint. Having proven hyaline cartilage growth in vitro (https://doi.org/10.1016/j.reth.2020.03.006) and their in vivo efficacy (https://doi.org/10.1016/j.jor.2017.01.003), EELS team has now proven that stem cell like progenitors and mesenchymal stem cells residing in the human cartilage could be grown without artificial reprogramming or animal proteins or feeder layers (https://doi.org/10.1016/j.jor.2021.01.005).

Hyaluranon (HA) in the matrix is essential for homeostasis of cartilage, which is injected to treat cartilage damages in clinics and in the lab, added from external sources to support chondrocyte culture. On the contrary, Dr Katoh`s team used a polymer scaffold that retains chondrocyte secreted HA to enhance their growth as a tissue, yielding higher HA content. This is another milestone in regenerative medicine, as it produces chondrocytes that are most suitable for clinical transplant with potentials for better healing and value addition to existing ACI and MACI procedures, after relevant clinical validation.

Further studies on miRNA-140, another essential cartilage component and the technologys anti-aging capabilities are underway to address debilitating joint diseases affecting millions worldwide in this method termed EELS-TALC, (Enriched with Essentials and Lapped in Scaffold, Transplant-suitable Autologous Leveraged Chondrocytes) in collaboration among EELS, JBM Inc and GN Corporation.

Scar-Forming Cells Switch to Producing New Neurons that Promote Functional Recovery in Mice after Spinal Cord Injury – Genetic Engineering &…

By adminMarch 8, 2021Stem Cell Medicine

Researchers at UT Southwestern (UTSW) and Indiana University have used genetic engineering techniques to trigger the production of functional nerve cells from scar-forming cells in mouse spinal cords, in response to spinal cord injury (SCI). The studies showed that neurogenic reprogramming of the spinal NG2 glial cells led to functional improvements in the animals after SCI, with the newly formed neurons rebuilding neuronal circuits.

The team hopes the achievement could point to new therapeutic approaches that could one day help the hundreds of thousands of people worldwide who suffer a spinal cord injury each year. The researchers, led by Chun-Li Zhang, PhD, professor of molecular biology and a W.W. Caruth, Jr. scholar in biomedical research at UTSW, reported their results in a paper in Cell Stem Cell, in which they concluded: Our results reveal a cellular and molecular mechanism underlying neural injury-induced cell plasticity that can be exploited for adult neurogenesis and relay formation in a region that has largely lost the ability to regenerate. Their report is titled, In vivo reprogramming of NG2 glia enables adult neurogenesis and functional recovery following spinal cord injury.

Cells in some body tissues proliferate after injury, replacing dead or damaged cells as part of healing. The brain itself does have limited capacity to produce new nerve cells, and this is possible thanks to progenitor cells that turn on distinct regenerative pathways. Adult neurogenesis in the brain plays critical roles in maintaining homeostasis and responding to neurological conditions, including injuries, Zhang and colleagues explained.

Chun-Li Zhang, PhD [UT Southwestern Medical Center]However, the spinal cord typically does not generate new neurons after injury, and this is a key barrier to recovery from SCI. Because the spinal cord acts as a signal relay between the brain and the rest of the body, Zhang added, this inability of the spinal cord to self repair permanently halts communication between these two areas, leading to paralysis, loss of sensation, and sometimes life-threatening consequences, such as an inability to control breathing or heart rate.

Using the knowledge of limited brain neurogenesis as inspiration, the researchers looked for cells that might have similar potential for regeneration in the spinal cord. Working with a mouse model of spinal cord injury, they looked in the animals injured spinal cords for a marker, DCX, that is normally found in immature neurons. DCX is normally expressed in neuroblasts and immature neurons and can serve as a reliable marker for adult neurogenesis, the team wrote. It is highly expressed in the developing spinal cord but completely turned off in the adult. Interestingly, they identified this marker in the spinal cord specifically after injury, and also tracked the marker to the non-neuronal NG2 glia cells, which produced it in response to SCI.

NG2 glia serve as progenitors for oligodendrocytes, cells that produce the insulating myelin layer that surrounds neurons. NG2 glia are also recognized as forming glial scars following injury. In response to injury, NG2 glia increase their numbers and become a major component of the glial scar, the scientists noted.

But the work by Zhangs team also showed that when the spinal cord in mice was injured, these glial cells transiently adopted molecular and morphological markers of immature neurons. To determine what caused the NG2 glia to change, the researchers focused on SOX2, a stem cell protein induced by injury. To understand how SCI induces cell reprogramming, we focused on SOX2, a stem cell factor essential for neurogenesis and neural development, the authors explained. our immunohistochemistry showed a 3.6-fold increase in the number of SOX2+ cells and the intensity of SOX2 expression in each cell surrounding the lesion site of the adult mouse spinal cord Most intriguingly, nearly all (94%) of the SCI-induced DCX+ cells co-expressed SOX2.

When the scientists then genetically manipulated NG2 cells to inactivate the gene that makes the SOX2 protein, they saw far fewer immature neurons in the days following SCI, suggesting that SOX2 plays a key role in helping NG2 glia make these new immature neurons. However, they also found that even with normal levels of SOX2, these immature neurons never matured into replacements for those affected by the injury. SCI only induces a transient phenotypic switch of NG2 glia to DCX+ cells, which eventually fail to become mature neurons, they wrote.

Zhang and his colleagues then used a different genetic manipulation technique to make NG2 glia overproduce SOX2. They found that in the weeks after spinal cord injury, mice with SOX2-overproducing NG2 glia generated tens of thousands of new mature neurons. Further investigation showed that these neurons integrated into the injured area, making the new connections with existing neurons that are necessary to relay signals between the brain and body.Even more promising, suggested Zhang, is that this genetic engineering led to functional improvements after spinal cord injury.

Encouragingly, animals engineered to overproduce SOX2 in their NG2 glia performed markedly better on motor skills weeks after spinal cord injury, when compared with animals that produced normal amounts of SOX2. The reasons for this improved performance seemed to be multifold. Not only had the animals generated neurons that appeared to take over for those damaged during injury, but they also had far less scar tissue at the injury site that could hinder recovery, Zhang explained. reprogramming of NG2 glia leads to generation of new neurons and reduction of glial scars, both of which may contribute to functional improvements after SCI, the team noted.

New spinal neurons converted from glia. [UT Southwestern Medical Center]They hope the results could lead to new strategies for identifying and developing safe and effective ways to overproduce SOX2 in human spinal cord injury patients, as an approach to helping repair injuries with new neurons, while reducing scar tissue formation. These results reveal a latent neurogenic potential of somatic glial cells, which can be leveraged for regenerative medicine, they concluded in their paper.

The field of spinal cord injury has extensively researched trying to heal the damage with stem cells that produce new neurons, but what were proposing here is that we may not need to transplant cells from the outside, Zhang said. By encouraging NG2 glia to make more SOX2, the body can make its own new neurons, rebuilding from within.

View post:
Scar-Forming Cells Switch to Producing New Neurons that Promote Functional Recovery in Mice after Spinal Cord Injury - Genetic Engineering &...

Moderna Hires Harvard Stem Cell Researcher Jonathan Hoggatt as Director of Hematology: What You Need to Know – Yahoo Finance

By adminMarch 8, 2021Stem Cell Medicine

TipRanks

Its time to check in with the macro picture, to get an idea of just where markets are headed in the coming months. Thats what a JPMorgan global research team, headed up by Joyce Chang, has been doing. The JPM team starts by noting the sell-off in US Treasury bonds last week, pushing up yields as investors acted in response to inflationary fears. However, the rise in bond yields steadied on Friday, and Changs team does not believe that inflation is the great bugaboo its made out to be; her team sees a combination of economic growth and fiscal stimulus creating a virtuous circle of consumer spending fueling more growth. They write, Our global economics team is now forecasting US nominal GDP to average roughly 7% growth over this year and next as targeted measures have been successful in addressing COVID-19 and economic activity is not being jeopardized. Global growth will exceed 5%... What this means, in JPMs view, is that the coming year should be good for stocks. Interest rates are likely to remain low, in the firms estimation, while inflation should moderate as the economy returns to normal. JPMs stock analysts have been following the strategy team, and seeking out the stocks they see as winners over the next 12 months. Three of their recent picks make for an interesting lot, with Strong Buy ratings from the analyst community and over 50% upside potential. Weve used the TipRanks database to pull the details on them. Lets take a look. On24 (ONTF) The first JPM pick were looking at here is On24, the online streaming service that offers third parties access for scaled and personalized networked events. In other words, On24 makes its streaming service available for other companies to use in setting up interactive features, including webinars, virtual events, and multi-media experiences. The San Francisco-based company boasts a base of more than 1900 corporate users. On24s customers engage online with more than 4 million professionals every month, for more than 42 million hours every year. As can be imagined, On24 saw a surge of customer interest and business in the past year, as virtual offices and telecommuting situations expanded and the company has now used that as a base for going public. On24 held its IPO last month, and entered the NYSE on February 3. The opening was a success; 8.56 million shares were put on the market at $77 each, well above the $50 initial pricing. However, shares have taken a beating since, and have dropped by 36%. Nevertheless, JPMs Sterling Auty thinks the company is well-placed to capitalize on current trends. The COVID-19 pandemic, we believe, has changed the face of B2B marketing and sales forever. It has forced companies to move most of their sales lead generation into the digital world where On24 is typically viewed as the best webinar/webcast provider. the 5-star analyst wrote. Even post-pandemic we expect the marketing motion to be hybrid with digital and in-person being equally important. That should drive further adoption of On24-like solutions, and we expect On24 to capture a material share of that opportunity. In line with these upbeat comments, Auty initiated coverage of the stock with an Overweight (i.e., Buy) rating, and his $85 price target suggests it has room for 73% upside over the next 12 months. (To watch Autys track record, click here.) Sometimes, a company is just so solid and successful that Wall Streets analysts line up right behind it and that is the case here. The Strong Buy analyst consensus rating is unanimous, based on 8 Buy-side reviews published since the stock went public just over a month ago. The shares are currently trading for $49.25 and their $74 average price target implies an upside of 50% from that level. (See On24s stock analysis at TipRanks.) Plug Power, Inc. (PLUG) And moving over to the reusable energy sector, well take a look at a JPM green power pick. Plug Power designs and manufactures hydrogen power cells, a technology with a great deal of potential as a possible replacement for traditional batteries. Hydrogen power cells have potential applications in the automotive sector, as power packs for alt-fuel cars, but also in just about any application that involves the storage of energy home heating, portable electronics, and backup power systems, to name just a few. Over the past year, PLUG shares have seen a tremendous surge, rising over 800%. The stock got an additional boost after Joe Bidens presidential election win and his platform promises to encourage Green Energy. But the stock has pulled back sharply recently, as many over-extended growth names have. Poor 4Q20 results also help explain the recent selloff. Plug reported a deep loss of $1.12 per share, far worse than the 8-cent loss expected, or the 7-cent loss reported in the year-ago quarter. In fact, PLUG has never actually reported positive earnings. This company is supported by the quality of its technology and that techs potential for adoption as industry moves toward renewable energy sources but we arent there yet, despite strides in that direction. The share price retreat makes PLUG an attractive proposition, according to JPM analyst Paul Coster. In the context of the firm's many long-term growth opportunities, we believe the stock is attractively priced at present, ahead of potential positive catalysts, which include additional pedestal customer wins, partnerships and JVs that enable the company to enter new geographies and end-market applications quickly and with modest capital commitment, the analyst said. At present, PLUG is a story stock, appealing to thematic investors as well as generalists seeking exposure to Renewable Energy growth, and Hydrogen in particular. Costers optimistic comments come with an upgrade to PLUGs rating - from a Neutral (i.e., Hold) to Overweight (Buy) - and a $65 price target that indicates a possible 55% upside. (To watch Costers track record, click here.) Plug Power has plenty of support amongst Costers colleagues, too. 13 recent analyst reviews break down to 11 Buys and 1 Hold and Sell, each, all aggregating to a Strong Buy consensus rating. PLUG shares sell for $39.3 and have an average price target of $62.85, which suggests a 60% one-year upside potential. (See Plugs stock analysis at TipRanks.) Orchard Therapeutics, PLC (ORTX) The last JPM stock pick well look at is Orchard Therapeutics, a biopharma research company focused on the development of gene therapies for the treatment of rare diseases. The companys goal is to create curative treatments from the genetic modification of blood stem cells treatments which can reverse the causative factors of the target disease with a single dosing. The companys pipeline features two drug candidates that have received approval in the EU. The first, OTL-200, is a treatment for Metachromatic leukodystrophy (MLD), a serious metabolic disease leading to losses of sensory, motor, and cognitive functioning. Strimvelis, the second approved drug, is a gammaretroviral vector-based gene therapy, and the first such ex vivo autologous gene therapy to receive approve by the European Medicines Agency. It is a treatment for adenosine deaminase deficiency (ADA-SCID), when the patient has no available related stem cell donor. In addition to these two EU-approved drugs, Orchard has ten other drug candidates in various stages of the pipeline process, from pre-clinical research to early-phase trials. Anupam Rama, another of JPMs 5-star analysts, took a deep dive into Orchard and was impressed with what he saw. In his coverage of the stock, he notes several key points: Maturing data across various indications in rare genetic diseases continues to de-risk the broader ex vivo autologous gene therapy platform from both an efficacy / safety perspective Key opportunities in MLD (including OTL-200 and other drug candidates) have sales potential each in the ~$200-400M range Importantly, the overall benefit/risk profile of Orchards approach is viewed favorably in the eyes of physicians. At current levels, we believe ORTX shares under-reflect the risk-adjusted potential of the pipeline... The high sales potential here leads Rama to rate the stock as Outperform (Buy) and to set a $15 price target, implying a robust 122% upside potential in the next 12 months. (To watch Ramas track record, click here.) Wall Street generally is in clear agreement with JPM on this one, too. ORTX shares have 6 Buy reviews, for a unanimous Strong Buy analyst consensus rating, and the $15.17 average price target suggests a 124% upside from the current $6.76 trading price. (See Orchards stock analysis at TipRanks.) Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Continue reading here:
Moderna Hires Harvard Stem Cell Researcher Jonathan Hoggatt as Director of Hematology: What You Need to Know - Yahoo Finance

NK Cell Therapy and Stem Cell Therapy Market Size, Industry Analysis, Growth Factors, Trends, and Regional Forecast to 2027 – KSU | The Sentinel…

By adminMarch 8, 2021Stem Cell Clinics

GlobalNK Cell Therapy and Stem Cell Therapy Market2021 by Company, Regions, Type, and Application, Forecast to 2025 dispatched byMarket Research Storeinvolves all the major information as for the market covering wide assessment of industry divides. The report presents pieces of information into the overall business near to the market estimations and appraisal for the range 2020 to 2025. The report gives an itemized investigation of the market status, venture plans, creation and utilization, value patterns, and examination by the market player, by area, by type, by the application. While inspecting the worldwide NK Cell Therapy and Stem Cell Therapy market, the market momentum stream and examples, industry improvement drivers, piece of the pie, deals volume, enlightening graphs, flexibility and request, and various perspectives were contemplated.

Report Focuses:

The report covers industry patterns in the worldwide market to assist players with creating compelling long haul techniques. Business development systems received by created and creating markets are featured. The report examines late improvements to comprehend the serious market situation and request. Market patterns and viewpoint combined with factors driving and limiting the development of the worldwide NK Cell Therapy and Stem Cell Therapy market. Point by point review and division of the worldwide market, just as its elements in the business, are given.

NOTE:Our investigators observing the circumstance over the globe clarifies that the market will create gainful possibilities for makers post COVID-19 emergency. The report means to give an extra outline of the most recent situation, monetary stoppage, and COVID-19 effect on the general business.

DOWNLOAD FREE SAMPLE REPORT:http://www.marketresearchstore.com/report/global-nk-cell-therapy-and-stem-cell-therapy-753684#RequestSample

A portion of the significant market players that are recorded in the report are:Chipscreen Biosciences, Innate Pharma SA, Osiris Therapeutics, Chiesi Pharmaceuticals, Molmed, JCR Pharmaceutical, Altor BioScience Corporation, Affimed NV, Takeda Pharmaceutical, Pharmicell, Medi-post, NuVasive, Anterogen

Market fragment by item types thinking about creation, income (esteem), value patterns:NK Cell Therapy, Stem Cell Therapy

Market section by applications considering utilization development rate and piece of the overall industry:Hospital & clinics, Regenerative medicine centers, Diagnostic centers, Research institutes, Others

The exploration offers an investigation of the topographical scene of the worldwide NK Cell Therapy and Stem Cell Therapy market, which is separated into locales, for example, North America (the United States, Canada, and Mexico), Europe (Germany, France, UK, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina, and so forth), Middle East and Africa (Saudi Arabia, Egypt, Nigeria, and South Africa)

Also, the report the ascent and falls that oppose the worldwide NK Cell Therapy and Stem Cell Therapy market significant commitment towards the ascending of the central participants in the main market is talked about. A selective examination of the variables that drive and limit market development is given in the worldwide NK Cell Therapy and Stem Cell Therapy market report. A broad examination of the critical portions of the business helps in understanding the patterns across local.

Key Questions Answered In This Report:

What is the market size of the worldwide NK Cell Therapy and Stem Cell Therapy industry?

This report covers the authentic market size of the business and figures for 2020 to 2025. Market size incorporates the complete incomes of organizations.

What is the standpoint for the business?

ACCESS FULL REPORT:http://www.marketresearchstore.com/report/global-nk-cell-therapy-and-stem-cell-therapy-753684

This report has market conjectures on the business, including all-out deals, various organizations, appealing venture openings, working costs, and others.

What number of organizations are in the business?

This report dissects the chronicled and anticipated number of organizations, areas in the worldwide NK Cell Therapy and Stem Cell Therapy industry, and separates them by organization size over the long run. The report additionally gives organization profiles regard to income, benefit correlation, operational effectiveness, cost seriousness, and market capitalization.

What are the monetary measurements for the business?

This report covers numerous monetary measurements for the business including productivity, market esteem chain, and key patterns affecting each portion concerning the organizations development, income, return on deals, and so on

About Us:

MarketResearchStore.comis a single destination for all the industry, company, and country reports. We feature a large repository of the latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations.

Contact the US:

Joel John Suite #8138, 3422 SW 15 Street, Deerfield Beach, Florida 33442 United States Toll Free: +1-855-465-4651 (USA-CANADA) Tel: +1-386-310-3803 Web:http://www.marketresearchstore.com Email:[emailprotected]

Stem Cell Therapies Market Current Scenario Trends, Comprehensive Analysis and Regional Forecast to – PharmiWeb.com

By adminMarch 8, 2021Stem Cell Clinics

VALLEY COTTAGE, N.Y. Impact of COVID-19 on the Healthcare Industry

The COVID-19 pandemic has caused severe impacts on the global economy at various levels and which can be seen on the Healthcare industry as well. The thriving market of health care research and development is expected to exhibit a steep decline in the sales during the lockdown period owing to the shutdown of the manufacturing units, acute shortage in the supply of raw materials and absence of potential manpower. It can be deduced from the current situations brought about by the pandemic that the production, and supply chain activities have experienced minor hurdles. However, the market is projected to gradually recover post-COVID-19, which will present attractive opportunities for sales across various regions of the world in the following years.

Future Market Insights (FMI) adopted a multidisciplinary approach during the pandemic-era to focus on the growth and development of the Stem Cell Therapies Market. The study features insights on the current growth dynamics and the major revenue reforms prevailing in the market as along with the key takeaways over the forecast.

The team of analysts at Future Market Insights are focussing on research and market study to produce different Stem Cell Therapies Market forecasts and predictions at both national and international levels. They have considered several leads of information pertaining to the industry like market figures and merger estimations to assess and produce reliable and informative insights on the Stem Cell Therapies Market.

To remain ahead of your competitors, Ask a Question >> https://www.futuremarketinsights.com/ask-question/rep-gb-1087

Key Players

The writer will create content on the general strategies of market players. And then will write the key players in the market are: Mesoblast Ltd, Roslin Cells, Regeneus Ltd, ReNeuron Group plc, International Stem Cell Corporation

Segmentation

The report provides insights on the important highlights and current trends prevailing in the market. This helps the readers to gain a deeper understanding and form an unbiased opinion on the market. Numerous segmentations have been provided for this market based on:

Based on treatment:

Based on application:

Based on End User:

Product Segmentation

The investigation offers a top to bottom evaluation of different clients journeys pertinent to the market and its segments.The study endeavours to assess the current and future development possibilities, undiscovered roads, factors that shapes their income potential in the global market by breaking it into di such as its types, applications, and region-wise assessment.

Get Access to Research Methodology Prepared by Experts >>https://www.futuremarketinsights.com/askus/rep-gb-1087

By Regional Analysis Covered

Full in-depth analysis of the parent market

The analysts at FMI are dedicated to provide insights after extensive research and study. The study also includes estimations, projections and evaluation of the market dynamics.

Important changes in market dynamics

The report has been created after detailed and exhaustive studies by the analysts at FMI taking several factors into consideration like monetary, ecological, social, mechanical, and political status of a particular demography. They study the key data to assess the revenue and production of manufacturers across various regions. The report also covers an in-depth analysis of the key changes in market dynamics in the recent past and the near future.

Segmentation details of the market

Queries Solved

To receive extensive list of important regions, ask for TOC here >>https://www.futuremarketinsights.com/toc/rep-gb-1087

Table of Content

Reasons to Buy the report

Explore Wide-ranging Coverage of FMIs Healthcare Landscape

Transradial Closure Devices Market According to Future Market Insights (FMI), the demand from hospitals, independent catheterization centers, and healthcare clinics will continue rising. Spurred by this, the global transradial closure devices market is set to grow by 6.5% CAGR during the forecast period from the year 2020 to 2030.

In Vitro Fertilization Banking Services Market The in vitro fertilization banking services market, despite undergoing a temporary period of lull due to COVID-19 outbreak, is likely to have an impressive growth trajectory between 2020 and 2030.

Cryopreservation for In-vitro Fertilization (IVF) Market According to analysis by Future Market Insights (FMI),cryopreservation for IVF market surpassed a valuation of US$ 339 millionin 2019. The market is set to reflect an impressive 10.2% CAGR through 2030.

About FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries.FMIis headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMIs latestmarket research reportsand industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Mr. Abhishek Budholiya Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers,Dubai, United Arab Emirates MARKET ACCESS DMCC Initiative For Sales Enquiries:sales@futuremarketinsights.com For Media Enquiries:press@futuremarketinsights.com Website:https://www.futuremarketinsights.com

Chemotherapy-Induced Myelosuppression Treatment Market 2021 Revenue, COVID Impact Analysis Report, I – PharmiWeb.com

By adminMarch 8, 2021Stem Cell Clinics

A new study by FMI reveals that the chemotherapy-induced myelosuppression treatment market is expected to grow at a subdued 3% y-o-y in 2019. Valued at nearly US$ 7 billion in 2018, gains are likely to be driven by a combination of multipronged factors, including,

The FMI study finds that growth factor drugs continued to garner highest revenues in thechemotherapy-induced myelosuppression treatment market. In 2018, over 73% of the chemotherapy-induced myelosuppression treatment market revenues were consolidated in the growth factors. Gains were especially notable for granulocyte-colony stimulating factor or G-CSF, which accounted for over 60% of the global chemotherapy-induced myelosuppression treatment market revenues in 2018.

The FMI study reveals that erythropoietin-stimulating agents (ESA) also accounted for a significant market share, with revenues likely to grow at 2.8% in 2019. In April 2017, FDA announced the removal of risk evaluation and mitigation strategy (REMS) requirement for the use of ESA drugs in myelosuppression treatment. The ESAs used in the treatment of radiation-induced myelosuppression treatment are epoetin alfa and darbepoetin alfa. This has led healthcare professionals to engage in the practice of discussing benefits as well as risks of treatments that include ESAs before initiating the use.

A sample of this report is available upon request @https://www.futuremarketinsights.com/reports/sample/rep-gb-1364

Hematopoietic growth factors have transformed the practice of cancer treatment by allowing stimulation of production of specific cells. With this, use of thrombopoietin receptor agonists is expected to rise rapidly at the rate of 3.5% in 2019.

Injectable Drugs Present Higher Therapeutic Availability over Orals

The FMI study finds that injectable drugs accounted for over 97% of the chemotherapy-induced myelosuppression treatment market revenues in 2018. The status-quo will continue in the future, however, the oral route of administration is expected to garner increasing annual revenues and expected to grow at 4.8% in 2019 over 2018.

Increasing number of research validations related to the benefits of the oral route of administration can be attributed to the higher growth rate of the segment in the future. However, revenues from the injectable route of the administration continue to grow steadily on the back of their higher therapeutic availability over orally administered drugs.

Market Revenues Consolidated in Neutropenia Treatment

According to the study, chemotherapy-induced myelosuppression treatment market revenues heavily consolidated in the neutropenia treatment. In 2018, neutropenia indication accounted for over 62% of market revenues. As neutropenia is one of the most common side effects of chemotherapy wherein prolongation of the same can lead to life-threatening infections. Owing to the severity of the implications, chemotherapy-induced myelosuppression therapeutics are heavily used in the treatment of neutropenia.

Anemia and thrombocytopenia indications also utilize chemotherapy-induced myelosuppression treatment therapeutics. The study finds that revenues in the thrombocytopenia treatment will grow at 3.7% y-o-y in 2019.

Preview Analysis On Global Chemotherapy-Induced Myelosuppression Treatment Market Segmentation byBy Drug Class (Growth Factors, Granulocyte Colony-Stimulating Factor, Thrombopoietin Receptor Agonists, Erythropoietin-stimulating Agents, Thrombopoietic Agents, Iron supplementation, Others);By Route of Administration (Oral, Injectable);By Indication (Anemia, Neutropenia, Thrombocytopenia)

Ask an Analyst @https://www.futuremarketinsights.com/ask-question/rep-gb-1364

Retail Pharmacies Most Prominent Sales Channel

The study opines that chemotherapy-induced myelosuppression treatment therapeutics sales remain higher through retail pharmacies. Suppliers of these therapeutics have extensive distribution network with international retail pharmacies. Due to this, retail pharmacies accounted for over 48% of the chemotherapy-induced myelosuppression treatment market revenues in 2018.

Owing to heavy integration of pharmacies in the hospitals, distribution of chemotherapy-induced myelosuppression treatment therapeutics through hospital pharmacies also account for a considerable share of the market revenues. The study finds that hospital pharmacies can be called the second largest distributor of chemotherapy-induced myelosuppression treatment therapeutics owing to their 45% of the market revenues.

US The Worlds Largest Chemotherapy-induced Myelosupression Treatment Market

FMI reveals that North America accounted for over 82% of the revenues in chemotherapy-induced myelosuppression treatment market in 2018. Presence of leading cancer therapeutics providers, significant R&D investments and established healthcare sector contribute to the bulk of market revenues. The U.S. remains the largest consumer of the chemotherapy-induced myelosuppression treatment market.

Market revenues in the APEJ region are likely to grow at higher rate owing to improving healthcare facility and growing penetration of advanced cancer care treatments. China, followed by India, accounts for the highest market revenues in APEJ owing to improving economic scenario and developing healthcare infrastructure.

Table Of Content

1. Executive Summary

2. Market Introduction

3. Chemotherapy-Induced Myelosuppression Treatment Market Opportunity Analysis

4. Market Background

5. Macroeconomic Assumptions

6. Global Economic Outlook

Request Report TOC @https://www.futuremarketinsights.com/askus/rep-gb-1364

7. Key Inclusions

8. Global Market Analysis 2013-2017 and Forecast 2018-2028

9. North America Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2017 and Forecast 2018-2028

10. Latin America Chemotherapy-Induced Myelosuppression Treatment Market Analysis 2013-2017 and Forecast 2018-2028

And So On

More from Healthcare, Pharmaceuticals and Medical Devices Market

Retinal Biologics MarketSegmentation by Drug Class (VEGF-An antagonist, TNF- inhibitor); by Indication (Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Uveitis, Others); by Distributional Channel (Institutional Sales, Retail Sales):https://www.futuremarketinsights.com/reports/retinal-biologics-market

Brain Monitoring System MarketSegmentation By Product Type (Functional Near-Infrared Spectroscopy (fNIRS), Electroencephalography (EEG) Systems, Magnetoencephalography (MEG) Systems, MRI Systems, Other Brain Monitoring Systems); By Modality (Portable/Handheld Systems, Standalone Systems); By End User (Hospitals, Ambulatory Surgical Centers, Clinics, Pediatric & Neonatal Intensive care Units):https://www.futuremarketinsights.com/reports/brain-monitoring-system-market

3D Cell Culture MarketSegmentation By Product Type (Scaffold-Free 3D Cell Culture, Scaffold-Based 3D Cell Culture); By Applications (Drug Discovery, Tissue Regeneration & Regenerative Medicines, Cancer Research, Stem Cell Technology, Others); By End User (Biotechnology and Pharmaceuticals Industries, Hospital Laboratories, Academic Research Institutes, Contract Research Organizations):https://www.futuremarketinsights.com/reports/3d-cell-culture-market

About FMI

Contact

Mr. Abhishek Budholiya Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates MARKET ACCESS DMCC Initiative For Sales Enquiries:sales@futuremarketinsights.com For Media Enquiries:press@futuremarketinsights.com

See original here:
Chemotherapy-Induced Myelosuppression Treatment Market 2021 Revenue, COVID Impact Analysis Report, I - PharmiWeb.com

Cell Therapy Company Raises $160 Million to Advance iPSC-Derived Therapies to Clinic – BioSpace

By adminMarch 8, 2021Stem Cell Clinic

Century Therapeuticsreceived a $160 million infusion of cash to advance the companys pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies for cancer.

This morning, the Philadelphia-based company announced a Series C financing round that will drive its preclinical pipeline, which includes multiple iPSC-derived CAR-iT and CAR-iNK cell products, into the clinic over the next 12 months. The companys assets are designed to resist host rejection, enhance cell persistence, and allow repeat dosing to provide durable responses in all patients. Century Therapeutics, which launched in 2019, anticipates clinical testing to begin in 2022 and also predicts it will generate multiple Investigational New Drug applications over the next several years.

The companysgenetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers. Centurys iPSCs, which are stem cells that can be generated from adult stem cells, have unlimited self-renewing capacity, which enables multiple rounds of cellular engineering. According to the company, these engineering rounds will produce master cell banks of modified cells that can be expanded and differentiated into immune effector cells to supply vast amounts of allogeneic and homogeneous therapeutic products. This platform differentiates Century from competitors that are developing cell therapies made from non-renewable donor-derived cells.

The Series C financing round was led by Casdin Capital and include a number of new investors, including Fidelity Management & Research LLC, the Federated HermesKauffmannFunds, RA Capital, Logos Capital, OrbiMed,Marshall Wace, Qatar Investment Authority, Avidity Partners, and Octagon Capital.Founding investorsVersant Ventures and Leaps by Bayer also participated in the latest fundraising.

We are fortunate to be surrounded by such a top-tier group of investors, whose support will enable the acceleration of Century's technology platform into the clinic, Lalo Flores, chief executive officer of Century Therapeutics said in a statement. With this new investor partnership, we are well-positioned to capitalize on the tremendous potential of our integrated iPSC, cell engineering and manufacturing capabilities to develop safer, more effective and more affordable next generation allogeneic cancer therapies.

Eli Casdin, chief investment of Casdin Capital, who joined the Century Therapeutics Board of Directors following this Series C, said he was excited to partner with the cell therapy company.

It's a remarkable and transformative time in the field, with the ability to engineer cells for therapeutic impact now a commercial reality. At the same time, iPSC technology has matured and is now leading the transition from bespoke autologous products to off-the-shelf allogeneic ones, Casdin said in a statement.

For Century Therapeutics, the financing round was announced about one month after the company expanded its capabilities with new laboratory manufacturing facilities in Pennsylvania and New Jersey. In addition to thePennsylvaniaandNew Jerseylocations, Century has a laboratory inHamilton, Ontariospecifically focused on targeting glioblastoma, and recently opened aSeattle-based innovation hub to help advance the company's novel iPSC platform and support the continued pipeline growth and development.

Last year, Century Therapeutics acquired Empirica Therapeutics to leverage its iPSC-derived allogeneic cell therapies against glioblastoma, one of the most common types of primary brain tumor in adults.

Retracing the Lineage of Cancer Cells – Technology Networks

By adminMarch 8, 2021Stem Cell Clinic

Read Time:

There is no stronger risk factor for cancer than age. At the time of diagnosis, the median age of patients across all cancers is 66. That moment, however, is the culmination of years of clandestine tumor growth, and the answer to an important question has thus far remained elusive: When does a cancer first arise?

At least in some cases, the original cancer-causing mutation could have appeared as long as 40 years ago, according to a new study by researchers at Harvard Medical School and the Dana-Farber Cancer Institute.

Reconstructing the lineage history of cancer cells in two individuals with a rare blood cancer, the team calculated when the genetic mutation that gave rise to the disease first appeared. In a 63-year-old patient, it occurred at around age 19; in a 34-year-old patient, at around age 9.

The findings, published in the March 4 issue ofCell Stem Cell, add to a growing body of evidence that cancers slowly develop over long periods of time before manifesting as a distinct disease. The results also present insights that could inform new approaches for early detection, prevention, or intervention.

"For both of these patients, it was almost like they had a childhood disease that just took decades and decades to manifest, which was extremely surprising," said co-corresponding study author Sahand Hormoz, HMS assistant professor of systems biology at Dana-Farber.

"I think our study compels us to ask, when does cancer begin, and when does being healthy stop?" Hormoz said. "It increasingly appears that it's a continuum with no clear boundary, which then raises another question: When should we be looking for cancer?"

In their study, Hormoz and colleagues focused on myeloproliferative neoplasms (MPNs), a rare type of blood cancer involving the aberrant overproduction of blood cells. The majority of MPNs are linked to a specific mutation in the gene JAK2. When the mutation occurs in bone marrow stem cells, the body's blood cell production factories, it can erroneously activate JAK2 and trigger overproduction.

To pinpoint the origins of an individual's cancer, the team collected bone marrow stem cells from two patients with MPN driven by the JAK2 mutation. The researchers isolated a number of stem cells that contained the mutation, as well normal stem cells, from each patient, and then sequenced the entire genome of each individual cell.

Over time and by chance, the genomes of cells randomly acquire so-called somatic mutations--nonheritable, spontaneous changes that are largely harmless. Two cells that recently divided from the same mother cell will have very similar somatic mutation fingerprints. But two distantly related cells that shared a common ancestor many generations ago will have fewer mutations in common because they had the time to accumulate mutations separately. Cell of origin

Analyzing these fingerprints, Hormoz and colleagues created a phylogenetic tree, which maps the relationships and common ancestors between cells, for the patients' stem cells--a process similar to studies of the relationships between chimpanzees and humans, for example.

"We can reconstruct the evolutionary history of these cancer cells, going back to that cell of origin, the common ancestor in which the first mutation occurred," Hormoz said.

Combined with calculations of the rate at which mutations accumulate, the team could estimate when the JAK2 mutation first occurred. In the patient who was first diagnosed with MPN at age 63, the team found that the mutation arose around 44 years prior, at the age of 19. In the patient diagnosed at age 34, it arose at age 9.

By looking at the relationships between cells, the researchers could also estimate the number of cells that carried the mutation over time, allowing them to reconstruct the history of disease progression.

"Initially, there's one cell that has the mutation. And for the next 10 years there's only something like 100 cancer cells," Hormoz said. "But over time, the number grows exponentially and becomes thousands and thousands. We've had the notion that cancer takes a very long time to become an overt disease, but no one has shown this so explicitly until now."

The team found that the JAK2 mutation conferred a certain fitness advantage that helped cancerous cells outcompete normal bone marrow stem cells over long periods of time. The magnitude of this selective advantage is one possible explanation for some individuals' faster disease progression, such as the patient who was diagnosed with MPN at age 34.

In additional experiments, the team carried out single-cell gene expression analyses in thousands of bone marrow stem cells from seven different MPN patients. These analyses revealed that the JAK2 mutation can push stem cells to preferentially produce certain blood cell types, insights that may help scientists better understand the differences between various MPN types.

Together, the results of the study offer insights that could motivate new diagnostics, such as technologies to identify the presence of rare cancer-causing mutations currently difficult to detect, according to the authors.

"To me, the most exciting thing is thinking about at what point can we detect these cancers," Hormoz said. "If patients are walking into the clinic 40 years after their mutation first developed, could we have caught it earlier? And could we prevent the development of cancer before a patient ever knows they have it, which would be the ultimate dream?"

The researchers are now further refining their approach to studying the history of cancers, with the aim of helping clinical decision-making in the future.

While their approach is generalizable to other types of cancer, Hormoz notes that MPN is driven by a single mutation in a very slow growing type of stem cell. Other cancers may be driven by multiple mutations, or in faster-growing cell types, and further studies are needed to better understand the differences in evolutionary history between cancers.

The team's current efforts include developing early detection technologies, reconstructing the histories of greater numbers of cancer cells, and investigating why some patients' mutations never progress into full-blown cancer, but others do.

"Even if we can detect cancer-causing mutations early, the challenge is to predict which patients are at risk of developing the disease, and which are not," Hormoz said. "Looking into the past can tell us something about the future, and I think historical analyses such as the ones we conducted can give us new insights into how we could be diagnosing and intervening."

Reference:Egeren DV, Escabi J, Nguyen M, et al. Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms. Cell Stem Cell. 2021;28(3):514-523.e9. doi:10.1016/j.stem.2021.02.001

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.